
    
      This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with
      dyslipidemia and Type II Diabetes.

      In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755
      for 16 weeks.

      In Metformin treatment group, 88 subjects will be assigned and the subjects administer
      Metformin for 16 weeks.

      In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer
      Rosuvastatin for 16 weeks.
    
  